News Releases

13 Jun '22
Cortexyme Appoints June Bray to its Board of Directors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 13, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray , a pharmaceutical industry veteran and global drug development and
PDF Version
20 May '22
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S.
PDF Version
20 May '22
Cortexyme Successfully Completes Acquisition of Novosteo
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of
PDF Version
10 May '22
Cortexyme Announces Agreement to Acquire Novosteo
Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporate name change to Quince
PDF Version
Displaying 1 - 10 of 18